These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11153825)

  • 1. Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction.
    Takenaka K; Yasuda S; Miyazaki S; Kurita T; Sutani Y; Morii I; Daikoku S; Kamakura S; Nonogi H
    Jpn Circ J; 2001 Jan; 65(1):60-2. PubMed ID: 11153825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reverse use-dependent QT prolongation during infusion of nifekalant in a case of recurrent ventricular tachycardia with old myocardial infarction.
    Shiga T; Ando S; Suzuki T; Matsuda N; Kasanuki H
    J Electrocardiol; 2001 Jan; 34(1):77-80. PubMed ID: 11239376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-arrhythmic efficacy of nifekalant hydrochloride, a pure class III anti-arrhythmic agent, in patients with healed myocardial infarction and inducible sustained ventricular tachycardia.
    Igawa M; Aonuma K; Okamoto Y; Hiroe M; Hiraoka M; Isobe M
    J Cardiovasc Pharmacol; 2002 Nov; 40(5):735-42. PubMed ID: 12409982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic effect of nifekalant on atrial tachyarrhythmia in four patients with severe heart failure.
    Shiga T; Matsuda N; Fuda Y; Haruta S; Hagiwara N; Kasanuki H
    J Cardiol; 2002 Mar; 39(3):159-64. PubMed ID: 11912950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis.
    Myoishi M; Yasuda S; Miyazaki S; Ueno K; Morii I; Satomi K; Otsuka Y; Kawamura A; Kurita T; Kamakura S; Nonogi H
    Circ J; 2003 Oct; 67(10):898-900. PubMed ID: 14578629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nifekalant hydrochloride, a novel class III antiarrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in a patient undergoing coronary artery bypass grafting and the Dor approach.
    Sahara M; Sagara K; Yamashita T; Iinuma H; Fu LT; Watanabe H
    Circ J; 2003 Aug; 67(8):712-4. PubMed ID: 12890916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart disease.
    Ando J; Kakishita M; Sakai K; Komura Y; Nishiyama K; Iwabuchi M; Yokoi H; Yasumoto H; Nosaka H; Nobuyoshi M
    Int Heart J; 2005 Jul; 46(4):647-56. PubMed ID: 16157956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with nifekalant hydrochloride in a patient with ischemic cardiomyopathy and severe ventricular dysfunction after dor operation.
    Kokaji K; Okamoto M; Hotoda K; Kumamaru H
    Jpn Heart J; 2004 Jul; 45(4):691-5. PubMed ID: 15353881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The efficiency of nifekalant hydrochloride for the prevention of ventricular tachycardia during cardiac surgery].
    Sakaguchi M; Takemura T; Shimamura Y; Tsuda Y; Iwasa S
    Kyobu Geka; 2004 Mar; 57(3):191-5. PubMed ID: 15035072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of pure potassium channel blocker nifekalant and sodium channel blocker mexiletine on malignant ventricular tachyarrhythmias.
    Otuki S; Hasegawa K; Watanabe H; Katsuumi G; Yagihara N; Iijima K; Sato A; Izumi D; Furushima H; Chinushi M; Aizawa Y; Minamino T
    J Electrocardiol; 2017; 50(3):277-281. PubMed ID: 28238302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of life-threatening ventricular tachyarrhythmia by a novel and pure class-III agent, nifekalant hydrochloride.
    Ohashi J; Yasuda S; Miyazaki S; Shimizu W; Morii I; Kurita T; Kawamura A; Kamakura S; Nonogi H
    J Cardiovasc Pharmacol; 2006 Dec; 48(6):274-9. PubMed ID: 17204905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative lusitropic property of nifekalant identified using ventricular pressure-volume loop analyses in anesthetized monkeys.
    Ishizaka T; Yoshimatsu Y; Maeda Y; Chiba K; Mori K
    Exp Anim; 2019 Feb; 68(1):91-102. PubMed ID: 30333366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nifekalant for acute conversion of atrial flutter: the possible termination mechanism of typical atrial flutter.
    Morita N; Tanaka K; Yodogawa K; Hayashi M; Akutsu K; Yamamoto T; Satoh N; Kobayashi Y; Katoh T; Takano T
    Pacing Clin Electrophysiol; 2007 Oct; 30(10):1242-53. PubMed ID: 17897127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia.
    Kamiya J; Ishii M; Katakami T
    Jpn J Pharmacol; 1992 Feb; 58(2):107-15. PubMed ID: 1507517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of efficacy of sotalol and nifekalant for ventricular tachyarrhythmias.
    Watanabe H; Chinushi M; Washizuka T; Sugiura H; Hirono T; Aizawa Y; Komura S; Hosaka Y; Tanabe Y; Furushima H; Aizawa Y
    Circ J; 2006 May; 70(5):583-7. PubMed ID: 16636494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model.
    Kondoh K; Hashimoto H; Nishiyama H; Umemura K; Ozaki T; Uematsu T; Nakashima M
    J Cardiovasc Pharmacol; 1994 Apr; 23(4):674-80. PubMed ID: 7516022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: post-marketing special investigation.
    Katoh T; Mitamura H; Matsuda N; Takano T; Ogawa S; Kasanuki H
    Circ J; 2005 Oct; 69(10):1237-43. PubMed ID: 16195624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nifekalant hydrochloride terminated electrical storms after coronary surgery.
    Kurisu K; Hisahara M; Onitsuka H; Sekiya M; Ikeuchi M; Kozai T; Urabe Y
    Ann Thorac Surg; 2010 May; 89(5):1637-9. PubMed ID: 20417798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of Nifekalant hydrochloride for life-threatening ventricular tachyarrhythmias in patients with resistance to lidocaine: a study of patients with out-of-hospital cardiac arrest].
    Amino M; Yoshioka K; Iwata O; Fujikura H; Deguchi Y; Ban K; Shiina Y; Goto S; Handa S; Tanabe T; Nakagawa Y; Morita S; Iwase H; Yamamoto I; Inokuchi S; Marutani Y
    J Cardiol; 2003 Mar; 41(3):127-34. PubMed ID: 12674997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.